Asarina Pharma AB (publ)FRA Asarina Pharma Stock Report

Asarina Pharma AB is a Swedish biotech company, which is engaged in developing Sepranolone for allopregnanolonerelated stress, menstrual and neurological disorders. The company is headquartered in Solna, Stockholm. The company went IPO on 2018-09-24. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The firm conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.